Glenmark Pharmaceuticals has introduced sacubitril + valsartan tablets for the treatment of heart failure in India. It is marketed as ‘Sacu V’ and must be taken twice daily with a doctor’s prescription. Its approved indication is to lower the risk of cardiovascular deaths and hospitalisations in patients with chronic heart failure (NYHA class II?IV) and a low ejection fraction (HFrEF).
The combination sacubitril/valsartan belongs to the ARNI class (Angiotensin receptor neprilysin inhibitor). In the treatment of heart failure, these molecules have two therapeutic targets: 1) the natriuretic peptide (NP) system for sacubitril and 2) the Renin Angiotensin System (RAS) for valsartan. The combination of sacubitril and valsartan has a long history of use in the treatment of patients with heart failure with reduced ejection fraction (HFrEF), and it is supported by the most recent heart failure treatment guidelines in Europe and the United States. Glenmark Pharmaceuticals is a global research-led pharmaceutical company with operations in over 50 countries and a presence in Generics, Specialty, and OTC.